View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

UK-Southampton: 18/187 Relapsing Polymyalgia Rheumatica
GB003ZM281084
National Institute for Health Research
13 December 2018
03 April 2019
Contract Notice - Other
No

Notice Abstract

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic: 18/187 Relapsing polymyalgia rheumatica Rationale: Polymyalgia rheumatica is an inflammatory condition affecting the muscles, particularly in the shoulders, neck and pelvic girdle. It most commonly occurs in older people of Scandinavian/northern European descent. Patients have severe pain and stiffness in the muscles as well as non-specific symptoms such as fatigue and loss of appetite. Increases in acute phase reactants such as C-reactive protein are common. The aetiology of polymyalgia rheumatica is unclear. Polymyalgia rheumatica is usually treated with corticosteroids which act to rapidly reduce inflammation, improving symptoms in the majority of patients. However, relapse is common following reduction of corticosteroid dose and patients are often treated for up to two years. As a result, they are at risk of adverse effects such as increased blood pressure, stomach ulcers and osteoporosis, the treatment of which potentially requires further use of NHS resources. Management of polymyalgia rheumatica with steroid-sparing agents such as disease-modifying anti-rheumatic drugs is therefore an attractive option. However, there is limited high quality evidence to demonstrate a benefit of using such agents in this condition. The addition of methotrexate to corticosteroids has been investigated in a few randomised studies that have reported mixed results. Evidence showing a benefit of treatment with leflunomide is limited to small case series. The HTA programme would therefore like to commission primary research to address this evidence gap and to inform clinical practice in this area.

Notice Details

CONTRACT NOTICE – NATIONAL

SERVICES

1 Authority Details

1.1

Authority Name and Address


National Institute for Health Research

N/A

Southampton


UK

N/A

N/A


N/A

1.2

Address from which documentation may be obtained

As in 1.1

1.3

Completed documents must be returned to:

As in 1.1

2 Contract Details

2.1

Title

18/187 Relapsing Polymyalgia Rheumatica

2.2

Description of the goods or services required

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:

18/187 Relapsing polymyalgia rheumatica

Rationale:

Polymyalgia rheumatica is an inflammatory condition affecting the muscles, particularly in the

shoulders, neck and pelvic girdle. It most commonly occurs in older people of

Scandinavian/northern European descent. Patients have severe pain and stiffness in the muscles

as well as non-specific symptoms such as fatigue and loss of appetite. Increases in acute phase

reactants such as C-reactive protein are common. The aetiology of polymyalgia rheumatica is

unclear.

Polymyalgia rheumatica is usually treated with corticosteroids which act to rapidly reduce

inflammation, improving symptoms in the majority of patients. However, relapse is common

following reduction of corticosteroid dose and patients are often treated for up to two years. As a

result, they are at risk of adverse effects such as increased blood pressure, stomach ulcers and

osteoporosis, the treatment of which potentially requires further use of NHS resources.

Management of polymyalgia rheumatica with steroid-sparing agents such as disease-modifying

anti-rheumatic drugs is therefore an attractive option. However, there is limited high quality

evidence to demonstrate a benefit of using such agents in this condition. The addition of

methotrexate to corticosteroids has been investigated in a few randomised studies that have

reported mixed results. Evidence showing a benefit of treatment with leflunomide is limited to

small case series. The HTA programme would therefore like to commission primary research to

address this evidence gap and to inform clinical practice in this area.

2.3

Notice Coding and Classification

2.4

Total quantity or scope of tender

3 Conditions for Participation

3.1

Minimum standards and qualification required

4 Administrative Information

4.1

Type of Procedure

The procedure type is unknown.

4.2

Reference number attributed to the notice by the contracting authority

18/187

4.3

Time Limits

   03-04-2019  Time 13:00

4.5

Language or languages in which tenders or requests to participate can be drawn up

EN 

4.6

Tender Submission Postbox

5 Other Information

5.1

Additional Information

Please visit the following portal to view this notice:

https://www.nihr.ac.uk/funding-and-support/funding-opportunities/18187-relapsing-polymyalgia-rheumatica/9701

The deadline for applications is 1pm, 3 April 2019.

(MT Ref:281084)

5.2

Additional Documentation

5.3

Publication date of this notice

 12-12-2018